Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $7.30 Consensus Target Price from Analysts

Esperion Therapeutics, Inc. (NASDAQ:ESPR) has earned a consensus rating of “Hold” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $7.30.

A number of analysts have commented on ESPR shares. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price target on shares of Esperion Therapeutics in a research report on Friday, December 13th. HC Wainwright reiterated a “buy” rating on shares of Esperion Therapeutics in a research report on Friday, January 10th. Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price target for the company. The Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price objective on the stock. Finally, StockNews.com cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th.

Institutional Investors Weigh In On Esperion Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ESPR. Bank of New York Mellon Corp increased its holdings in Esperion Therapeutics by 3,278.3% in the second quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock valued at $1,271,000 after buying an additional 555,382 shares in the last quarter. Rhumbline Advisers increased its stake in Esperion Therapeutics by 6,560.6% during the 2nd quarter. Rhumbline Advisers now owns 252,038 shares of the biopharmaceutical company’s stock worth $560,000 after buying an additional 248,254 shares in the last quarter. National Bank of Canada FI raised its stake in Esperion Therapeutics by 115.9% in the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 10,225 shares during the last quarter. American Century Companies Inc. acquired a new stake in shares of Esperion Therapeutics in the second quarter valued at about $50,000. Finally, BOKF NA purchased a new position in Esperion Therapeutics in the 2nd quarter worth approximately $26,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Trading Down 1.8 %

NASDAQ ESPR opened at $2.24 on Friday. Esperion Therapeutics has a 12-month low of $1.58 and a 12-month high of $3.94. The company has a fifty day simple moving average of $2.47 and a two-hundred day simple moving average of $2.18. The stock has a market cap of $441.36 million, a P/E ratio of -3.50 and a beta of 1.03.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.